anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an antiallergic agent acting on an immune system, being effective for prevention and amelioration of allergic symptom, and having high safety, to provide a method for producing the antiallergic agent, and to provide a composition for eating and drinking, and a composition for medicine or an animal medicine containing the antiallergic agent.  <P>SOLUTION: The antiallergic agent contains an alcohol-insoluble fraction of a digest of Vigna angularis by Aspergillus oryzae as an active ingredient. Preferably, the antiallergic agent is used for an eating and drinking material, a medicine or an animal medicine. The method for producing the antiallergic agent includes allowing the Vigna angularis to be digested by the Aspergillus oryzae, and adding an alcohol to an aqueous solution of the digest to provide a solid component as the alcohol-insoluble fraction. The composition for eating and drinking, for the medicine or for the animal medicine contains the antiallergic agent.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The subject invention relates to compositions of a polyphenolic Polymer and methods useful for the delivery of substantially water-insoluble drugs and agrochemicals, like Artemisinin, Aspirin, and Pyrethrin. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary polyphenolic partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary polyphenol molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable. More important the whole process and material used is GRAS approved and environmentally safe.
FIELD: medicine, pharmacy. SUBSTANCE: phytoconcentrate has a biologically active addition - quercitin or dihydroquercitin, or rutin, or ascorutin. Also, it contains medicinal plants - gourd, or squash, or musky gourd seeds, warty and pendent birch leaves, corn styles with stigmas, milfoil herb, meat, or chicken, or vegetable concentrate with special additions. Phytoconcentrate can be used at clinic and ambulatory conditions in different age groups and it shows good clinical results in patients with prostate diseases. EFFECT: enhanced effectiveness of a phytoconcentrate. 6 cl
Bone regrowth commonly occurs following lumbar decompression surgery. Although it is rare for neurological symptoms to occur due to bone regrowth, this study describes two patients who underwent both decompression and fusion surgeries but experienced spinal canal restenosisthat was severe enough to induce neurological symptoms. A 32-year-old man underwent posterior decompression and posterior lumbar interbody fusion for lumbar canal stenosis at the L4/L5 level 5 years prior. However, the sudden onset of lower back pain occurred 5 years later. Bone overgrowth on the left side was observed at the L4/L5 level. A second surgery was performed, and the patient's symptoms improved significantly. In the second case, a 56-year-old man underwent posterior decompression and posterior lumbar fusion at the L3/L4 and L4/L5 levels for an L4 burst fracture. One month later, he complained of lower back pain and underwent a second posterior decompression surgery. One year later, he presented to an outpatient clinic with lower back pain and neurological symptoms. Bone overgrowth was observed on both sides at the L4/L5 level. Thus, screw removal and laminectomy at the L3, L4, and L5 levels were performed as a third surgery. This study discusses the factors affecting bone regrowth and the methods that can be used to prevent it.
Postoperative ileus is common after surgery. One non-pharmacological intervention that has shown promising results in reducing the duration of postoperative ileus is chewing gum after surgery. However, this has not been investigated in upper gastrointestinal surgery such as pancreatic surgery. Hence the aim of this study was to investigate the effects of chewing gum treatment on patients undergoing pancreaticoduodenectomy due to pancreatic or periampullary cancer.

This study was conducted as a phase-III trial. Patients diagnosed with pancreatic tumours scheduled for pancreaticoduodenectomy were included. The treatment group received chewing gum postoperatively and standard care. Controls received glucose solution and standard care.
1281289 Unsaturated derivatives of aralkylamines MERCK & CO Inc 28 Sept 1970 [29 Sept 1969] 46061/70 Heading C2C Novel compounds of the Formulµ I and II wherein each of X and X<SP>1</SP> is hydrogen, halogen, alkyl, C 1-6  alkenyl, alkoxy, perfluoroalkyl, phenyl, substituted phenyl, C 1-4  alkyl-amino, di(C 1-4  alkyl)amino, hydroxy, C 1-4  perfluoroalkoxy, mercapto, C 1-4  perfluoroalkylthio, or alkylthio; .m is 1 to 4 and each of R 2  and R 3  is hydrogen, alkyl, aralkyl, alkenyl or alkynyl or R 2  and R 3  are bivalent hydrocarbon radicals joined to one another directly or through an atom of nitrogen, oxygen or sulphur to form, with the nitrogen atom that they are both attached to, a heterocyclic ring of 5 or 6 atoms or a non-toxic acid addition salt thereof may be prepared by reducing a cyano compound III with a metal hydride and optionally alkylating the amino group formed or treating a compound IV with ammonia or an amine. The cyano compound III may be prepared for acetylenic compounds III by dehydrobromination of a 2-cyano-stilbene dibromide V, to form the acetylenic bond or by substitution of cyano for bromo in a 2-bromo diphenylacetylene VI, or for olefinic compounds III by decarboxylation of a trans α-substituted 2-cyano cinnamic acid VIII and subsequent conversion of the cis 2-cyanostilbene to the trans isomer. The compounds VII may be prepared by condensation of a 2-cyano benzaldehyde with a phenyl acetic acid. The compounds VI may be prepared by dehydrobromination of a 2-bromostilbene dibromide. The 2-cyano stilbene dibromide V may be prepared by bromination of an olefinic compound IV. Pharmaceutical compositions of the compounds I and II show antiarrhythmic activity when administered orally or parenterally with the usual excipients.
We will evaluate the performance of HindSight in a randomized controlled trial (RCT). HindSight is a novel encoding software designed to optimize alerts for sepsis alert notification. HindSight identifies clinicians' sepsis-related decisions in the electronic health records of former patients and passes those events to InSight, thus supplying InSight with labeled examples of true positive sepsis cases for retraining. In our retrospective work, we have shown that HindSight enables InSight to adapt to site-specific deviations of real-world clinical deployment by successfully reducing false and irrelevant alarms, without human supervision. The goal of this project is to demonstrate that the retrospective success of HindSight can be successfully translated to live clinical environments. In our Phase I work, HindSight achieved an area under the receiver-operating characteristic (AUROC) of 0.899, 0.831 and 0.877 for clinician sepsis evaluation, treatment, and onset, respectively. By using an online learning algorithm to incorporate HindSight-labeled data into the InSight predictor, we showed that the online-trained InSight can adapt to the HindSight-labeled data and outperform both baseline and periodically re-trained versions of InSight (p \< 0.05). In Aim 1, we will prospectively validate HindSight's performance on real-time patient data streams in three diverse hospitals non-interventionally. In Aim 2, we will evaluate the effect of the tool in a prospective, interventional RCT. HindSight will first be evaluated by live deployment at four academic and community hospitals, during which time it will not provide alerts of future sepsis onset. Following any necessary algorithm optimization arising from live hospital validation, we will perform an RCT to evaluate reductions in false alerts from InSight trained on HindSight sepsis labels (experimental arm), compared to InSight trained on gold standard Sepsis-3 labels (control arm).
The aberrant expression of Stratifin (SFN) is intricately associated with the initiation and progression of numerous tumors. This study aims to investigate whether SFN regulates the metastasis of cervical cancer cells through the LIMK2/Cofilin signaling pathway. In this study, we compared the expression of SFN in normal cervical tissues and cervical carcinoma tissues. We established SFN overexpression and SFN silencing cellular models to assess the invasive and migratory capabilities of cervical cancer cells using transwell and scratch assays. YO-PRO-1/PI and EdU staining were employed to evaluate apoptotic and proliferative capacities, while Actin-Tracker Green-488 was utilized to investigate cytoskeletal remodeling. The expression levels of SFN, LIMK2, p-LIMK2, Cofilin, and p-Cofilin were examined through Western blotting and immunofluorescence. Our findings revealed elevated expression of SFN in cervical squamous cell carcinoma tissues. SFN overexpression was observed to enhance invasion and migration of cervical cancer cells, induce cytoskeletal remodeling, facilitate cell proliferation, and suppress apoptosis. Furthermore, SFN overexpression upregulated the expression levels of LIMK2, p-LIMK2, Cofilin, and p-Cofilin. Conversely, silencing SFN exerted opposite effects. SFN plays an important role in the diagnosis of cervical cancer. SFN can regulate cervical cancer cell proliferation, apoptosis, cytoskeletal remodeling and metastasis through LIMK2/Cofilin signaling.
Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
Most people post-stroke are confronted with important sensorimotor deficits of the upper-limb. The identification of clinical, kinematic and MRI biomarkers seems preliminary to i) understand recovery mechanisms, ii) model recovery, and iii) to optimize and personalize rehabilitation strategies that favors adaptive cerebral plasticity and diminish functional deficits.

MAPPY is a complementary study to the interregional PHRC MARGAUT (Medical Adaptive Rehabilitation Games for Arm Use Therapy, EudraCT/ID RCB 2010-A00596-33, Clinical Trial: NCT01554449). Data will be available for 21 participants post-stroke and 12 healthy controls. It includes 1/ clinical data (clinical patient characteristics, Fugl-Meyer Upper Limb scores, Box and Block Test, Wolf Motor Function test, Motor Activity Log), 2/ kinematic data of an elbow flexion/extension task within the fMRI, and 3/ fMRI data (Diffusion images, T2, FLAIR, perfusion, and vascular imaging, 3DT1, fMRI, fMRI resting-state).

It has already been established that isolated clinical evaluation cannot provide a reliable recovery prognosis, nor allow for precise personalization of rehabilitation protocols. In contrast, it has been demonstrated that kinematic movement characteristics can have an additional value concerning the prognosis and evolution of recovery. Finally, changes in clinical and kinematic characteristics are thought to reflect cerebral reorganization. Its principal processes are well described: extended activations around the lesioned area, activation of secondary motor areas and additional activation of regions in the contralesional hemisphere. However, how these changes are linked to actual behavior remains less clear. In healthy people there seems to be a link between control strategies and kinematic characteristics. In addition, post-stroke, links between movement smoothness and secondary motor area recruitment have been described. Therefore, the longitudinal and multimodal approach applied in this study offers the unique opportunity to study functional connectivity early post-stroke as well as its evolution after 6 weeks of rehabilitation. Functional connectivity will be confronted with changes in anatomical connectivity, kinematic movement characteristics, clinical scores, and the initial and final stroke volume and its penumbra. The investigators aim to characterize cerebral plasticity via cerebral connectivity post-stroke and its evolution over recovery, as well as to identify biomarkers to predict motor recovery immediately post-stroke by integrating clinical, kinematic and MRI data to progress towards a personal modilisation of motor recovery post-stroke.
OBJECTIVE: To investigate the outcomes of aqueous shunt exposure repair and to identify risk factors for recurrent exposure after surgical repair.
METHODS: This is a retrospective interventional case series of consecutive patients who underwent repair of an exposed aqueous shunt. Demographic and clinical data were extracted from the patients' records and survival analysis was employed to determine the probability of survival of the repair without further exposure. Cox proportional regression analysis was utilised to identify potential risk factors for failure of the repair surgery.
RESULTS: Seventy-six eyes of 76 patients were included in the study. The probability of survival without further exposure was 76.2% (CI 66.9-86.8%), 72.7% (CI 62.8-84.1%) and 54.7% (40.5-73.7%) at 1,2 and 4 years, respectively. No eye in which the tube was repositioned in the anterior chamber or in the sulcus (n = 9; 11.8%) developed a recurrence of the exposure. A shorter interval from the time of tube insertion to the repair surgery (HR 2.87 [CI 1.11-7.39]; p = 0.03; reference longer interval), a history of previous surgical revision (HR 3.06 [1.15-8.12]; p = 0.02; reference no prior revision) and the use of a human pericardial donor patch at the time of revision (HR 3.43 [1.16-10.13]; p = 0.03; reference other than pericardium) was associated with an increased risk of exposure recurrence.
CONCLUSION: Aqueous shunt exposure revision is associated with reasonable mid and long term success. A shorter interval from tube insertion to exposure revision, previous revisions and the use of a human pericardium patch were associated with increased risk of failure.
The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
Retinal inflammation is a pivotal characteristic observed in various retinal degenerative disorders, notably age-related macular degeneration (AMD), primarily orchestrated by the activation of microglia. Targeting the inhibition of microglial activation has emerged as a therapeutic focal point. Quercetin (Qu), ubiquitously present in dietary sources and tea, has garnered attention for its anti-neuroinflammatory properties. However, the impact of Qu on retinal inflammation and the associated mechanistic pathways remains incompletely elucidated. In this study, retinal inflammation was induced in adult male C57BL/6 J mice through intraperitoneal administration of LPS. The results revealed that Qu pre-treatment induces a phenotypic shift in microglia from M1 phenotype to M2 phenotype. Furthermore, Qu attenuated retinal inflammation and stabilized the integrity of the blood-retina barrier (BRB). In vitro experiments revealed that Qu impedes microglial activation, proliferation, and migration, primarily via modulation the ERK/STAT3 signaling pathway. Notably, these actions of Qu significantly contributed to the preservation of photoreceptors. Consequently, Qu pre-treatment holds promise as an effective strategy for controlling retinal inflammation and preserving visual function.
Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. patient controlled analgesia (PCA) protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
The present invention relates to a method for producing cancerous disease modifying antibodies (CDMAB). Antibodies generated in mice, upon immunization with malignant cells of human lung adenocarcinoma tumour tissue are screened for cytotoxicity against a variety of cancer cell lines. An anti-cancer cytotoxic monoclonal antibody (mAb) is isolated, produced by the hybridoma AR1 04A1666.2.8 deposited with IDAC as Accession Number 181207-01, which is cytotoxic to human lung cancer cell lines, and reduces tumour burden in a human breast cancer xenograft model. The mAb also binds to several cancer cell lines but is not cytotoxic in a non-cancerous cell line. This mAb can be used to treat primary tumours and tumour metastases. This mab can be conjugated to toxms, enzymes, radioactive compounds, and hematogenous cells.
Liquid compns. which form cohesive, flexible moulds at body temperature. For diagnosis of internal malformations, particularly in the large intestine. The compns. preferably consist of a liquid elastomeric substance, a vulcanising or polymerising agent, an anti-swelling agent, and X-ray opaque matter. The compn. must be sufficiently liquid for injection into the cavity and just lose its fluidity rapidly after injection, preferably endothermically, or with only slight exothermicity. After X-ray diagnosis, the substance is removed; in the case of colonic injection, preferably by defecation.
Young adults born preterm (less than 37 weeks gestation) have alterations in the structure and function of the heart, with similar changes observed in preterm infants in the first three months of life. It is unknown whether these early changes in the heart seen in the first few months of life are relevant to long-term changes in heart structure and function. Heart changes have also not been well studied in children born preterm. To investigate this, the study will follow up children from the EPOCH study and will perform two study visits for each child (n=100 preterm and n=100 term) that will use echocardiography and cardiovascular magnetic resonance. Individuals in the EPOCH study had echocardiography measures done at birth and three months postnatal age. It will therefore be possible to do longitudinal echocardiography measures from birth up to ages 12 years to determine whether postnatal heart changes in preterm infants track into childhood. Cardiovascular magnetic resonance will allow for the determination of whether these early heart changes influence heart pump function. Finally, by measuring lung function, blood vessel structure and function, and blood pressure, it will be possible to determine how heart changes relate to other components of the cardiovascular system. This data will be used to confirm the relevance of early heart remodelling in preterm-born offspring over time and provide more comprehensive heart phenotyping for preterm-born children. Together, this information can be used to design future intervention strategies in preterm-born individuals to reduce cardiovascular risk in this growing subgroup of the population.
Participants will receive acupuncture, five times per day form pre-operation to 3 days after operation. The selected acupoints include RN3,RN4, bilateral ST36,SP6,SP9 and LR3. All acupoints areas have been sterilized before acupuncture. needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. Arrival of Qi by acupuncture and needle retaining for 20 minutes.
Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
OBJECTIVE: This study sought to develop and validate a 6-year risk prediction model in older adults with cognitive frailty (CF).
METHODS: In the secondary analysis of Chinese Longitudinal Healthy Longevity Survey (CLHLS), participants from the 2011-2018 cohort were included to develop the prediction model. The CF was assessed by the Chinese version of Mini-Mental State Exam (CMMSE) and the modified Fried criteria. The stepwise regression was used to select predictors, and the logistic regression analysis was conducted to construct the model. The model was externally validated using the temporal validation method via the 2005-2011 cohort. The discrimination was measured by the area under the curve (AUC), and the calibration was measured by the calibration plot. A nomogram was conducted to vividly present the prediction model.
RESULTS: The development dataset included 2420 participants aged 60 years or above, and 243 participants suffered from CF during a median follow-up period of 6.91 years (interquartile range 5.47-7.10 years). Six predictors, namely, age, sex, residence, body mass index (BMI), exercise, and physical disability, were finally used to develop the model. The model performed well with the AUC of 0.830 and 0.840 in the development and external validation datasets, respectively.
CONCLUSION: The study could provide a practical tool to identify older adults with a high risk of CF early. Furthermore, targeting modifiable factors could prevent about half of the new-onset CF during a 6-year follow-up.
PROBLEM TO BE SOLVED: To obtain a cosmetic having an appearance of a transparent feeling, a refreshing feeling in application to skin, uniform finish and excellent durability of dry feeling, etc., by including a granule containing powder subjected to specific water-repellent treatment. SOLUTION: A cosmetic contains 1-30 wt.% of a granule containing powder subjected to water-repellent treatment having <=0.1 kgf/mm<2> , preferably <=0.02 kgf/mm<2> compression strength in cosmetic. Arbitrary inorganic or organic powder is used as mother powder to be subjected to water-repellent treatment. The average particle diameter of the mother powder is preferably about 0.1-100 μm. A fluorine compound, a silicone oil, lecithin or the like may be cited as the water-repellent treating agent and a perfluoroalkyl phosphate is especially preferable. The content of the water-repellent treating agent in the granule is >=50 wt.%. The average particle diameter of the granule is preferably >=50 μm and <500 μm. The cosmetic preferably contains water and ethanol in the ratio of 99/1 to 50/50 by weight.
Present invention is related to a waterborne polyurethane material with stem cells non-irritability for cells healing having a waterproof and moisture permeable layer being stacked with a functional adhesive layer. The waterproof and moisture permeable layer is made of waterborne polyurethane material having a hard segment and a soft segment being polymerized together. The hard segment has an aliphatic isocyanate and a chain prolonged agent. The chain prolonged agent may be EDA or PDA. The soft segment has a polyol and a chain extender. The polyol may be polyether polyol or polyester polyol. The chain extender may be DMPA. By choosing biocompatible material and process control, the present invention has stem cells non-irritability and is able to use on cells healing purposes which is suitable for applying on biomedical applications.